[go: up one dir, main page]

PL3529251T3 - Pochodne naftyrydynonu i ich zastosowanie w leczeniu arytmii - Google Patents

Pochodne naftyrydynonu i ich zastosowanie w leczeniu arytmii

Info

Publication number
PL3529251T3
PL3529251T3 PL17801105.2T PL17801105T PL3529251T3 PL 3529251 T3 PL3529251 T3 PL 3529251T3 PL 17801105 T PL17801105 T PL 17801105T PL 3529251 T3 PL3529251 T3 PL 3529251T3
Authority
PL
Poland
Prior art keywords
arrhythmia
treatment
naphthyridinone derivatives
naphthyridinone
derivatives
Prior art date
Application number
PL17801105.2T
Other languages
English (en)
Inventor
Guillaume Barbe
Gregory Raymond Bebernitz
Sicong GENG
Hatice Belgin Gulgeze Efthymiou
Lv LIAO
Fupeng Ma
Ruowei MO
David Thomas Parker
Yunshan Peng
Stefan Peukert
Ken Yamada
Kayo Yasoshima
Nichola Smith
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3529251T3 publication Critical patent/PL3529251T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17801105.2T 2016-10-21 2017-10-19 Pochodne naftyrydynonu i ich zastosowanie w leczeniu arytmii PL3529251T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662410930P 2016-10-21 2016-10-21
CN2016102928 2016-10-21
US201662413292P 2016-10-26 2016-10-26
PCT/IB2017/056515 WO2018073788A1 (en) 2016-10-21 2017-10-19 Naphthyridinone derivatives and their use in the treatment of arrhythmia

Publications (1)

Publication Number Publication Date
PL3529251T3 true PL3529251T3 (pl) 2023-01-30

Family

ID=60409317

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17801105.2T PL3529251T3 (pl) 2016-10-21 2017-10-19 Pochodne naftyrydynonu i ich zastosowanie w leczeniu arytmii

Country Status (32)

Country Link
US (3) US10266531B2 (pl)
EP (2) EP4141006A1 (pl)
JP (1) JP7030802B2 (pl)
KR (1) KR102540872B1 (pl)
CN (1) CN109843887B (pl)
AU (2) AU2017344489C1 (pl)
CA (1) CA3038624A1 (pl)
CL (1) CL2019001023A1 (pl)
CO (1) CO2019003894A2 (pl)
CR (1) CR20190201A (pl)
CU (1) CU24599B1 (pl)
DO (1) DOP2019000100A (pl)
EC (1) ECSP19026973A (pl)
ES (1) ES2934234T3 (pl)
FI (1) FI3529251T3 (pl)
HR (1) HRP20221516T1 (pl)
HU (1) HUE060882T2 (pl)
IL (1) IL266128B (pl)
JO (1) JOP20190086A1 (pl)
LT (1) LT3529251T (pl)
MX (1) MX390044B (pl)
PE (1) PE20190735A1 (pl)
PH (1) PH12019500849A1 (pl)
PL (1) PL3529251T3 (pl)
PT (1) PT3529251T (pl)
RS (1) RS63841B1 (pl)
SA (1) SA519401614B1 (pl)
SG (1) SG11201902529WA (pl)
SI (1) SI3529251T1 (pl)
TW (1) TWI759343B (pl)
UY (1) UY37445A (pl)
WO (1) WO2018073788A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
MX2020013373A (es) 2018-06-27 2021-03-09 Bristol Myers Squibb Co Compuestos de naftiridinona utiles como activadores de celulas t.
WO2022074567A1 (en) 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia
CN115677739B (zh) * 2021-07-31 2025-09-30 华南理工大学 一种o,o-二氟化硼配合物的制备方法
AR127698A1 (es) * 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
EP4574830A4 (en) * 2022-09-23 2025-11-26 Guangzhou Vinnocent Pharmaceutical Ltd PYRIDINE INHIBITOR, RINGED STEROID SYNTHETASE, ITS PREPARATION PROCESS AND ITS USE
US20240391941A1 (en) * 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
IL51092A0 (en) 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
JPS57176958A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation
JPS57176959A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation
JPS57176956A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176957A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0787720B1 (en) 1994-10-20 2003-07-16 Wakunaga Seiyaku Kabushiki Kaisha Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
ATE269320T1 (de) 1996-04-19 2004-07-15 Wakunaga Pharma Co Ltd Neue pyridoncarbonsäure-derivate oder salze dieser derivate und antibakterielle mittel, die diese als aktiven wirkstoff enthalten
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
EP0945435B1 (en) 1996-11-28 2003-08-13 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AU5509099A (en) 1998-08-03 2000-02-28 Basf Corporation Pyridinones for the treatment of sexual dysfunction
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6521607B1 (en) 1999-09-23 2003-02-18 Pharmacia Corporation (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
AR032316A1 (es) 2000-04-12 2003-11-05 Novartis Ag Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica
JP2003040866A (ja) 2001-07-31 2003-02-13 Nippon Kayaku Co Ltd Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤
PL369531A1 (pl) 2001-09-26 2005-05-02 Bayer Pharmaceuticals Corporation Pochodne 1,8-naftyrydyny jako środki przeciwcukrzycowe
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2005529160A (ja) 2002-05-31 2005-09-29 バイエル・フアーマシユーチカルズ・コーポレーシヨン 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物
EP1537114B8 (en) 2002-08-07 2007-10-03 Novartis AG Organic compounds as agents for the treatment of aldosterone mediated conditions
JP2006508970A (ja) 2002-11-18 2006-03-16 ノバルティス アクチエンゲゼルシャフト イミダゾ［１，５ａ］ピリジン誘導体およびアルデステロンにより仲介される疾患の処置方法
WO2005026164A1 (en) 2003-09-18 2005-03-24 Altana Pharma Ag Pharmacologically active imidazo[4,5-c]pyridines
JP4719681B2 (ja) 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリンカリウムチャネル阻害剤
AU2005230915A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
JP2008500998A (ja) 2004-05-28 2008-01-17 シュペーデル・エクスペリメンタ・アーゲー 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用
DE602005025110D1 (de) 2004-05-28 2011-01-13 Novartis Ag Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
CA2568159A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
AR049711A1 (es) 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
MX2008000141A (es) 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
CA2631082C (en) 2005-11-23 2015-02-03 Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
CN101415803B (zh) 2006-04-04 2012-10-24 大阳日酸株式会社 甲烷分离方法、甲烷分离装置以及甲烷利用系统
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
JP2010501573A (ja) 2006-08-25 2010-01-21 ノバルティス アクチエンゲゼルシャフト アルドステロン合成酵素および／または１１−β−ヒドロキシラーゼおよび／またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体
US20100041722A1 (en) 2006-12-18 2010-02-18 Qi-Ying Hu Organic compounds
CA2673119A1 (en) 2006-12-18 2008-06-26 Novartis Ag 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
MX2009006631A (es) 2006-12-18 2009-06-30 Novartis Ag Imidazoles como inhibidores de sintasa de aldosterona.
ES2354008T3 (es) 2007-03-29 2011-03-09 Novartis Ag Compuestos espiroheterocíclicos.
MY156226A (en) * 2008-02-22 2016-01-29 Otsuka Pharma Co Ltd Benzodiazepine compound and pharmaceutical composition
WO2010012745A2 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
EP2549276B1 (en) 2009-08-10 2015-02-25 UCL Business PLC Reversible covalent linkage of functional molecules
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
KR101477156B1 (ko) 2010-08-25 2014-12-29 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
BR112014000499A2 (pt) 2011-07-12 2017-01-10 Hoffmann La Roche compostos de quinolona de aminometila
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
CA2873861C (en) 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
US9067894B1 (en) 2013-03-07 2015-06-30 Vanderbilt University Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014152317A2 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating gonorrhea infections using quinolone antibiotics
AR096022A1 (es) 2013-04-11 2015-12-02 Basf Se Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales
WO2015019347A1 (en) 2013-08-08 2015-02-12 Yeda Research And Development Company Ltd. Girk as a therapeutic target of immune disorders and a marker of b cell subtypes
US20160326165A1 (en) 2013-12-26 2016-11-10 Kinki University Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug
EP3182974A1 (en) 2014-08-21 2017-06-28 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
KR20180016485A (ko) * 2015-06-09 2018-02-14 바이엘 파마 악티엔게젤샤프트 무스카린성 m2 수용체의 양성 알로스테릭 조정제
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Also Published As

Publication number Publication date
US10844055B2 (en) 2020-11-24
HRP20221516T1 (hr) 2023-02-17
CA3038624A1 (en) 2018-04-26
EP3529251A1 (en) 2019-08-28
AU2017344489B2 (en) 2020-04-02
CL2019001023A1 (es) 2019-06-21
BR112019007863A2 (pt) 2019-07-02
IL266128B (en) 2021-06-30
TW201819377A (zh) 2018-06-01
US20210284635A1 (en) 2021-09-16
US11530213B2 (en) 2022-12-20
FI3529251T3 (fi) 2023-01-13
CR20190201A (es) 2019-06-04
EP3529251B1 (en) 2022-10-05
CU24599B1 (es) 2022-06-06
WO2018073788A1 (en) 2018-04-26
SA519401614B1 (ar) 2022-06-12
CN109843887B (zh) 2022-05-10
AU2020204341A1 (en) 2020-07-16
AU2020204341B2 (en) 2021-07-01
JOP20190086A1 (ar) 2019-04-18
ES2934234T3 (es) 2023-02-20
AU2017344489A1 (en) 2019-04-11
RU2019115344A (ru) 2020-11-24
EP4141006A1 (en) 2023-03-01
HUE060882T2 (hu) 2023-04-28
CU20190042A7 (es) 2019-11-04
SI3529251T1 (sl) 2023-01-31
CO2019003894A2 (es) 2019-04-30
AU2017344489C1 (en) 2021-12-23
IL266128A (en) 2019-06-30
KR20190066052A (ko) 2019-06-12
PH12019500849A1 (en) 2019-12-02
ECSP19026973A (es) 2019-04-30
US20190263803A1 (en) 2019-08-29
MX390044B (es) 2025-03-20
PT3529251T (pt) 2022-12-23
US20180111932A1 (en) 2018-04-26
DOP2019000100A (es) 2019-06-16
MX2019004484A (es) 2019-08-05
JP2019531326A (ja) 2019-10-31
UY37445A (es) 2018-05-31
KR102540872B1 (ko) 2023-06-08
TWI759343B (zh) 2022-04-01
SG11201902529WA (en) 2019-05-30
US10266531B2 (en) 2019-04-23
CN109843887A (zh) 2019-06-04
JP7030802B2 (ja) 2022-03-07
LT3529251T (lt) 2023-01-10
RS63841B1 (sr) 2023-01-31
RU2019115344A3 (pl) 2021-02-20
PE20190735A1 (es) 2019-05-23

Similar Documents

Publication Publication Date Title
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
HUE037558T2 (hu) Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
IL273177A (en) Fluorophenyl beta-hydroxyethylamines and their uses in the treatment of hyperglycemia
PL3615035T3 (pl) Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii
SG11202104571RA (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
ZA201704726B (en) Peptides and their use in the treatment of skin
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
IL266198A (en) Liposomal formulation for use in cancer treatment
ZA201904966B (en) Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
ZA201904967B (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
GB201604213D0 (en) Drug combination and its use in therapy
PL3722291T3 (pl) Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
SG11201802955VA (en) Peptides of use in the preventive and curative treatment of alopecia
HK40020424A (en) Sulfinylpyridines and their use in the treatment of cancer
HK40020425A (en) Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
HK40020423A (en) Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
HK40020422A (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
HK40021223A (en) Bicyclic compounds and their use in the treatment of cancer
HK40013929A (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
AU2016905362A0 (en) Compounds and use thereof in methods of treatment
PT3152193T (pt) Derivados de tetra-hidroisoquinolinona e sua utilização na inibição da proteína hsp70